Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Genet Med ; 22(2): 381-388, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31488898

RESUMEN

PURPOSE: To outline structures for regional genetic services support centers that improve access to clinical genetic services. METHODS: A workgroup (WG) and advisory committee (AC) (1) conducted a comprehensive review of existing models for delivering health care through a regional infrastructure, especially for genetic conditions; (2) analyzed data from a needs assessment conducted by the National Coordinating Center (NCC) to determine important components of a regional genetic services support center; and (3) prioritized components of a regional genetic services support system. RESULTS: Analysis of identified priorities and existing regional systems led to development of eight models for regional genetic services support centers. A hybrid model was recommended that included an active role for patients and families, national data development and collection, promotion of efficient and quality genetic clinical practices, healthcare professional support for nongeneticists, and technical assistance to healthcare professionals. CONCLUSION: Given the challenges in improving access to genetic services, especially for underserved populations, regional models for genetic services support centers offer an opportunity to improve access to genetic services to local populations. Although a regional model can facilitate access, some systemic issues exist-e.g., distribution of a workforce trained in genetics-that regional genetic services support centers cannot resolve.


Asunto(s)
Servicios Genéticos/tendencias , Aceptación de la Atención de Salud/estadística & datos numéricos , Programas Médicos Regionales/tendencias , Servicios Genéticos/estadística & datos numéricos , Pruebas Genéticas/estadística & datos numéricos , Pruebas Genéticas/tendencias , Personal de Salud , Humanos , Evaluación de Necesidades , Grupos de Población , Estados Unidos
2.
Genet Med ; 22(1): 241, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31551579

RESUMEN

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

3.
Mol Genet Metab ; 118(4): 221-9, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27268406

RESUMEN

UNLABELLED: Newborn screening (NBS) is intended to identify congenital conditions prior to the onset of symptoms in order to provide early intervention that leads to improved outcomes. NBS is a public health success, providing reduction in mortality and improved developmental outcomes for screened conditions. However, it is less clear to what extent newborn screening achieves the long-term goals relating to improved health, growth, development and function. We propose a framework for assessing outcomes for the health and well-being of children identified through NBS programs. The framework proposed here, and this manuscript, were approved for publication by the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). This framework can be applied to each screened condition within the Recommended Uniform Screening Panel (RUSP), recognizing that the data elements and measures will vary by condition. As an example, we applied the framework to sickle cell disease and phenylketonuria (PKU), two diverse conditions with different outcome measures and potential sources of data. Widespread and consistent application of this framework across state NBS and child health systems is envisioned as useful to standardize approaches to assessment of outcomes and for continuous improvement of the NBS and child health systems. SIGNIFICANCE: Successful interventions for newborn screening conditions have been a driving force for public health newborn screening for over fifty years. Organizing interventions and outcome measures into a standard framework to systematically assess outcomes has not yet come into practice. This paper presents a customizable outcomes framework for organizing measures for newborn screening condition-specific health outcomes, and an approach to identifying sources and challenges to populating those measures.


Asunto(s)
Anemia de Células Falciformes/diagnóstico , Tamizaje Neonatal/normas , Fenilcetonurias/diagnóstico , Anemia de Células Falciformes/epidemiología , Anemia de Células Falciformes/genética , Niño , Preescolar , Humanos , Recién Nacido , Tamizaje Neonatal/tendencias , Fenilcetonurias/genética , Fenilcetonurias/patología , Salud Pública
4.
Can Vet J ; 62(11): 1245, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34728856
5.
Genet Med ; 14(12): 951-4, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22899090

RESUMEN

Newborn screening is performed under public health authority, with analysis carried out primarily by public health laboratories or other centralized laboratories. Increasingly, opportunities to improve infant health will arise from including screening tests that are completed at the birth centers instead of in centralized laboratories, constituting a significant shift for newborn screening. This report summarizes a framework developed by the US Secretary of Health and Human Services Advisory Committee on Heritable Disorders in Newborns and Children based on a series of meetings held during 2011 and 2012. These meetings were for the purpose of evaluating whether conditions identifiable through point-of-care screening should be added to the recommended universal screening panel, and to identify key considerations for birth hospitals, public health agencies, and clinicians when point-of-care newborn screening is implemented.


Asunto(s)
Tamizaje Neonatal/economía , Sistemas de Atención de Punto/economía , Programas de Gobierno , Personal de Salud , Pérdida Auditiva/congénito , Pérdida Auditiva/diagnóstico , Cardiopatías Congénitas/diagnóstico , Humanos , Recién Nacido , Tamizaje Neonatal/legislación & jurisprudencia , Tamizaje Neonatal/normas , Sistemas de Atención de Punto/legislación & jurisprudencia , Sistemas de Atención de Punto/normas , Guías de Práctica Clínica como Asunto , Rol Profesional , Salud Pública , Estados Unidos
7.
JAMA Neurol ; 76(8): 978-983, 2019 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-31107518

RESUMEN

IMPORTANCE: Newborn screening (NBS) identifies infants with specific congenital disorders for which earlier intervention cannot only prevent a lifetime of chronic disability but also, most importantly, save lives. In this article, we discuss complexities associated with NBS processes in the United States, with a focus on challenges in neuromuscular disorders. OBSERVATIONS: As new interventions for neuromuscular disorders become available, the clinical community must prepare to overcome the challenges of adding new diseases to screening panels and understand the rigorous evidence review at the federal level and the complex process of state-level implementation. In this regard, NBS programs for Pompe disease and spinal muscular atrophy can guide the path of Duchenne muscular dystrophy and other neuromuscular disorders as future candidates for NBS. CONCLUSIONS AND RELEVANCE: The availability of advanced screening methods, the emergence of effective treatment, and the support of professional organizations may facilitate the expansion of NBS, such that an increasing number of infants can be identified in the newborn period who will benefit from life-saving interventions.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA